Analysis of Clinical Features of Chronic Liver Disease Complicated With Hepatopulmonary Syndrome

Study Overview
=================
Brief Summary
-----------------
Hepatopulmonary syndrome (HPS) has unknown pathogenesis, limited treatment and poor prognosis. The onset of HPS is insidious and easy to be ignored. Many liver diseases such as cirrhosis and related complications are the core characteristics of Beijing You 'an Hospital, but the clinical characteristics of HPS patients in the center are still unclear. The investigators plan to make the diagnosis of HPS among chronic liver disease patients in the hospital according to the diagnostic criteria of HPS proposed in the Practice Guidelines of the International Society of Liver Transplantation in 2016, collect clinical data of HPS participants, evaluate the severity, analyze and summarize clinical characteristics, and conduct management and follow-up. At the same time, The investigators collect blood samples for proteomics tests. In order to improve the diagnosis and treatment level of HPS.

Detailed Description
-----------------
At present, the mechanism of hepatopulmonary syndrome is not clear. The researchers plan to use the extracted plasma for detection, protein extraction and quality control, and then proteolytic hydrolysis, computer detection, and bioinformatics analysis.

Official Title
-----------------
Analysis of Clinical Features of Chronic Liver Disease Complicated With Hepatopulmonary Syndrome

Conditions
-----------------
Hepatopulmonary Syndrome (HPS)

Intervention / Treatment
-----------------
* Biological: Proteomic sequencing


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: chronic hepatitis Agreed to venous blood collection Exclusion Criteria: pneumonia, pulmonary vascular disease, interstitial pulmonary disease, COPD, bronchial asthma, lung cancer and other primary pulmonary diseases, acute upper gastrointestinal bleeding.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 100 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Chronic liver disease with hepatopulmonary syndrome<br>Liver disease (usually cirrhosis with portal hypertension) ；Positive CE-TTE（Contrast enhanced contrast ultrasound）；Abnormal arterial oxygenation: Alveolar-arterial oxygen gradient (AaO2) ≥ 15 mm Hg (>20 mm Hg if age > 64) | Biological: Proteomic sequencing<br>* Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups<br>|
| Chronic liver disease without hepatopulmonary syndrome<br>Liver disease (usually cirrhosis with portal hypertension) ； Negative CE-TTE | Biological: Proteomic sequencing<br>* Proteomic sequencing, bioinformatics analysis，find abnormal indicators between two groups<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Proteomic results of participants | Qualitative and quantitative analysis of proteome | April 1,2024 |